Veru Inc. (VERU) stock
VERUNasdaqPharmaceutical PreparationsFiscal year ends September 30
$2.08−0.01 (-0.48%)
Close on Nov 16, 2026Market cap $35.46MP/E –Yield –
Veru EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Veru's EPS for the twelve months ending Jun 30, 2026 was -$0.58. For fiscal 2023 it was -$11.00. The highest annual figure on record is $5.30 in fiscal 2012.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2023 | Sep 30, 2023 | -$11.00 | – |
| FY2022 | Sep 30, 2022 | -$10.50 | -1266.7% |
| FY2021 | Sep 30, 2021 | $0.90 | – |
| FY2020 | Sep 30, 2020 | -$2.80 | – |
| FY2019 | Sep 30, 2019 | -$1.90 | – |
| FY2018 | Sep 30, 2018 | -$4.40 | – |
| FY2017 | Sep 30, 2017 | -$2.50 | -2600.0% |
| FY2016 | Sep 30, 2016 | $0.10 | -93.3% |
| FY2015 | Sep 30, 2015 | $1.50 | +87.5% |
| FY2014 | Sep 30, 2014 | $0.80 | -84.0% |
| FY2013 | Sep 30, 2013 | $5.00 | -5.7% |
| FY2012 | Sep 30, 2012 | $5.30 | +178.9% |
| FY2011 | Sep 30, 2011 | $1.90 | -20.8% |
| FY2010 | Sep 30, 2010 | $2.40 | 0.0% |
| FY2009 | Sep 30, 2009 | $2.40 | – |
Quarterly eps
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | -$0.30 | – |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | -$0.12 | – |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | -$0.26 | – |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | $0.10 | – |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | -$0.50 | – |
| Q2 FY2025CQ1 2025 | Mar 31, 2025 | -$0.54 | – |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | -$0.61 | – |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | -$0.58 | – |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | -$0.75 | – |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | -$0.70 | – |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | -$0.80 | – |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | -$0.90 | – |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | -$1.40 | – |
| Q2 FY2023CQ1 2023 | Mar 31, 2023 | -$4.20 | – |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | -$4.80 | – |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | -$5.14 | – |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | -$2.80 | – |
| Q2 FY2022CQ1 2022 | Mar 31, 2022 | -$1.80 | -178.3% |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | -$0.80 | – |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | -$0.30 | – |
| Q2 FY2021CQ1 2021 | Mar 31, 2021 | -$0.40 | – |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | $2.30 | – |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | -$1.69 | – |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | -$0.50 | – |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | -$0.10 | – |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | -$0.50 | – |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | -$0.47 | – |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | -$0.40 | – |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | -$0.60 | – |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | -$0.30 | – |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | -$1.44 | – |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | -$1.50 | – |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | -$0.70 | – |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | -$0.80 | – |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | -$1.20 | – |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | -$0.30 | – |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | -$0.60 | – |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | -$0.40 | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | -$0.60 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?